retatrutide data Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Data and thoughts - 3

Description

Key Findings

GLP-1 Agents vs Aspirin: A Contemporary Comparison Viewed through a modern prevention lens, aspirin and GLP-1 agents represent two distinct strategies for colorectal cancer prevention

Additional indications Knee osteoarthritis, sleep apnea, MASLD, cardiovascular outcomes, and chronic low back pain would follow based on their respective trial timelines This mirrors how Lilly handled tirzepatide: Mounjaro was approved for diabetes first (May 2022), followed by Zepbound for obesity (November 2023)

By indication, the type 2 diabetes mellitus segment held a dominant position in the market with a 58% share in 2025

Tesofensine may be suitable for individuals who have struggled with obesity and have not achieved significant weight loss through diet and exercise alone